The Journal of Practical Medicine >
Role and mechanism of XPOT inhibition by atractylenolide I in gastric cancer cells
Received date: 2023-09-25
Online published: 2024-07-15
Objective This study aimed to investigate the role and mechanism of atractylenolide I in inhibiting XPOT proliferation and invasion in gastric cancer cells. Methods This study included exploration of XPOT expression in gastric cancer tissues， analysis of gene expression data from GC patients in TCGA and GEO databases， as well as various cellular assays to detect the ability of cancer cells to proliferate， migrate， and invade. Protein expression levels of XPOT， SKP2， CyclinA， and P27 mRNA were also detected by qPCR and Western Blot. Results Analysis confirmed that XPOT was highly expressed in gastric cancer tissues， indicating a poor prognosis. In vitro studies revealed that AT-1 inhibits the proliferation and invasion ability of GC cells； XPOT down-regulation also inhibits these abilities. Furthermore， AT-1 down-regulates the expression of XPOT which then regulates SKP2， P27， and CyclinA - ultimately inhibiting the proliferation and invasion of gastric cancer cells through the regulation of the XPOT pathway. Conclusion The overexpression of XPOT in gastric cancer tissues can indicate a poor prognosis. Atractylenolide I down-regulates the XPOT-regulated ubiquitination-proteasome pathway to inhibit proliferation and invasion of gastric cancer cells.
Yi ZHANG , Fangqi MA , Siyuan WEI , Xuejun. LI . Role and mechanism of XPOT inhibition by atractylenolide I in gastric cancer cells[J]. The Journal of Practical Medicine, 2024 , 40(14) : 1928 -1934 . DOI: 10.3969/j.issn.1006-5725.2024.14.005
| 1 | NORWOOD D A， MONTALVAN-SANCHEZ E， DOMINGUEZ R L， et al. Gastric Cancer： Emerging Trends in Prevention， Diagnosis， and Treatment ［J］. Gastroenterol Clin North Am， 2022， 51（3）： 501-518. doi:10.1016/j.gtc.2022.05.001 |
| 2 | LORDICK F， CARNEIRO F， CASCINU S， et al. Gastric cancer： ESMO Clinical Practice Guideline for diagnosis， treatment and follow-up ［J］. Ann Oncol， 2022， 33（10）： 1005-1020. doi:10.1016/j.annonc.2022.07.004 |
| 3 | THRIFT A P， EL-SERAG H B. Burden of Gastric Cancer ［J］. Clin Gastroenterol Hepatol， 2020， 18（3）： 534-542. doi:10.1016/j.cgh.2019.07.045 |
| 4 | LI K， ZHANG A， LI X， et al. Advances in clinical immunotherapy for gastric cancer ［J］. Biochim Biophys Acta Rev Cancer， 2021， 1876（2）： 188615. doi:10.1016/j.bbcan.2021.188615 |
| 5 | LI G Z， DOHERTY G M， WANG J. Surgical Management of Gastric Cancer： A Review ［J］. JAMA Surg， 2022， 157（5）： 446-454. doi:10.1001/jamasurg.2022.0182 |
| 6 | 吴珍珍，刘志宏，孙丽. PTEN诱导激酶1在预测胃癌患者预后及化疗疗效中的作用［J］. 实用医学杂志， 2021，37（10）：1272-1278. doi:10.3969/j.issn.1006-5725.2021.10.008 |
| 7 | 宋早智，王庆康，孙家和，等. DOT1L在胃癌组织中的表达及其与预后的相关性［J］. 实用医学杂志， 2019，35（22）：3498-3502. doi:10.3969/j.issn.1006-5725.2019.22.015 |
| 8 | 郭晨旭，刘静波，谢强，等. 白术内酯Ⅰ通过调低Cyclin D1/CDK4抑制胃癌细胞SGC-7901的增殖及机制［J］. 蚌埠医学院学报， 2020，45（4）：456-460. doi:10.13898/j.cnki.issn.1000-2200.2020.04.009 |
| 9 | DENG M， CHEN H， LONG J， et al. Atractylenolides （I， II， and III）： a review of their pharmacology and pharmacokinetics ［J］. Arch Pharm Res， 2021， 44（7）： 633-654. doi:10.1007/s12272-021-01342-6 |
| 10 | BAILLY C. Atractylenolides， essential components of Atractylodes-based traditional herbal medicines： Antioxidant， anti-inflammatory and anticancer properties ［J］. Eur J Pharmacol， 2021， 891： 173735. doi:10.1016/j.ejphar.2020.173735 |
| 11 | MA L， MAO R， SHEN K， et al. Atractylenolide I-mediated Notch pathway inhibition attenuates gastric cancer stem cell traits ［J］. Biochem Biophys Res Commun， 2014， 450（1）： 353-359. doi:10.1016/j.bbrc.2014.05.110 |
| 12 | LI Y， WANG Y， LIU Z， et al. Atractylenolide I Induces Apoptosis and Suppresses Glycolysis by Blocking the JAK2/STAT3 Signaling Pathway in Colorectal Cancer Cells ［J］. Front Pharmacol， 2020， 11： 273. doi:10.3389/fphar.2020.00273 |
| 13 | LONG F， LIN H， ZHANG X， et al. Atractylenolide-I Suppresses Tumorigenesis of Breast Cancer by Inhibiting Toll-Like Receptor 4-Mediated Nuclear Factor-κB Signaling Pathway ［J］. Front Pharmacol， 2020， 11： 598939. doi:10.3389/fphar.2020.598939 |
| 14 | TRULSSON F， AKIMOV V， ROBU M， et al. Deubiquitinating enzymes and the proteasome regulate preferential sets of ubiquitin substrates ［J］. Nat Commun， 2022， 13（1）： 2736. doi:10.1038/s41467-022-30376-7 |
| 15 | TOMA-FUKAI S， SHIMIZU T. Structural Diversity of Ubiquitin E3 Ligase ［J］. Molecules， 2021， 26（21）：6682. doi:10.3390/molecules26216682 |
| 16 | DIKIC I， SCHULMAN B A. An expanded lexicon for the ubiquitin code ［J］. Nat Rev Mol Cell Biol， 2023， 24（4）： 273-287. doi:10.1038/s41580-022-00543-1 |
| 17 | CRUZ WALMA D A， CHEN Z， BULLOCK A N， et al. Ubiquitin ligases： guardians of mammalian development ［J］. Nat Rev Mol Cell Biol， 2022， 23（5）： 350-367. doi:10.1038/s41580-021-00448-5 |
| 18 | DANG F， NIE L， WEI W. Ubiquitin signaling in cell cycle control and tumorigenesis ［J］. Cell Death Differ， 2021， 28（2）： 427-438. doi:10.1038/s41418-020-00648-0 |
| 19 | LIN J， HOU Y， HUANG S， et al. Exportin-T promotes tumor proliferation and invasion in hepatocellular carcinoma ［J］. Mol Carcinog， 2019， 58（2）： 293-304. doi:10.1002/mc.22928 |
| 20 | PAN L J， CHEN J L， WU Z X， et al. Exportin-T： A Novel Prognostic Predictor and Potential Therapeutic Target for Neuroblastoma ［J］. Technol Cancer Res Treat， 2021， 20： 15330338211039132. doi:10.1177/15330338211039132 |
| 21 | KOKONTIS J M， LIN H P， JIANG S S， et al. Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2， CyclinA， and Skp2 ［J］. PloS One， 2014， 9（10）： e109170. doi:10.1371/journal.pone.0111731 |
| 22 | SEXTON R E， HALLAK M N AL， DIAB M， et al. Gastric cancer： a comprehensive review of current and future treatment strategies ［J］. Cancer Metastasis Rev， 2020， 39（4）： 1179-1203. doi:10.1007/s10555-020-09925-3 |
| 23 | XIA J Y， AADAM A A. Advances in screening and detection of gastric cancer ［J］. J Surg Oncol， 2022， 125（7）： 1104-1109. doi:10.1002/jso.26844 |
| 24 | AJANI J A， D'AMICO T A， BENTREM D J， et al. Gastric Cancer， Version 2.2022， NCCN Clinical Practice Guidelines in Oncology ［J］. J Natl Compr Canc Netw， 2022， 20（2）： 167-192. |
| 25 | 李相辉，侯艳红，吴凯，等. TXNDC5 siRNA靶向纳米微粒对胃癌模型动物抑瘤作用的实验研究［J］. 实用医学杂志， 2023，39（13）：1634-1640. doi:10.3969/j.issn.1006-5725.2023.13.007 |
| 26 | CAI Z， MOTEN A， PENG D， et al. The Skp2 Pathway： A Critical Target for Cancer Therapy ［J］. Semin Cancer Biol， 2020， 67（Pt 2）： 16-33. doi:10.1016/j.semcancer.2020.01.013 |
/
| 〈 |
|
〉 |